Aurelie Najm AurelieRheumo
1 week 2 days ago
No big surprise here, deucravacitinib does as well without MTX
Pooled analysis of 52wk data of POETYK PSA
Same ACR20/50/70 and MDA response profiles also similar safety profiles
#POS0288 #EULAR2026 @RheumNow https://t.co/XqLfZstRuS
Jiha Lee JihaRheum
1 week 3 days ago
Oral TYK2i deucravacitinib works for #PsA with OR without methotrexate. Pooled POETYK data (n=648): ACR20/50/MDA, enthesitis, dactylitis, skin responses, and PROs all comparable regardless of MTX use at wk 52. Good news for pts who can't tolerate MTX. @RheumNow #EULAR2026 POS0288
Aurelie Najm AurelieRheumo
1 week 3 days ago
What does remission look like for people living with PsA?
Much more than the absence of swollen joints
Absence of pain
Skin management
Ability to resume daily activities
Sustained over time
A definition not always reflected in our disease activity scores
#POS0294 #EULAR2026 https://t.co/VCnMGAOVYm
sheila RHEUMarampa
1 week 3 days ago
In this posthoc analysis of pooled data from BE MOBILE 1&2, BKZ showed ⬆️clinical imprvements vs. PBO at 1 yr regardless of age, BMI, HLAB27 status & CRP.
At wk 52, ASAS40/ASDAS <2.1 was higher in pts w/BKZ who were ≤35y, BMI ≥25–<30 or HLA-B27+
POS0949 @RheumNow #EULAR2026 https://t.co/9sfil6y5Qr
Antoni Chan MD (Prof) synovialjoints
1 week 3 days ago
Double targeted therapy in refractory SpA/PsA.
76 patients, 17 Spanish centres, up to 6 years follow-up. Median 4 prior biologics.
Remission achieved in 55.6% during follow-up. 28.6% in remission at final visit.
ASDAS improved significantly from 3 months, sustained to 5 https://t.co/g1IPstYYuX
sheila RHEUMarampa
1 week 3 days ago
10yr ffup data on 49pts from the OG CRESPA study (GOL vs PBO in very early pSpA):
81.6% (40/49) were in clinical remission
15 pts on drug-free remission
21 pts w/remission on meds still on GOL, no unSSAEs
Early aggressive tx is key!
AbsPOS0931 @RheumNow #EULAR2026 https://t.co/HrTF5XtAZt
Antoni Chan MD (Prof) synovialjoints
1 week 3 days ago
PET-derived parameters in #PsA correlated with DAPSA, CRP and patient pain. Angiogenesis imaging may be a complementary biomarker of overall disease burden Abstr#OP068 #EULAR2026 #Imaging
Antoni Chan MD (Prof) synovialjoints
1 week 3 days ago
Treat-to-target in inflammatory arthritis recommended by every guideline. Followed in only 40% of SpA visits.
The main reason was activity simply wasn’t documented using a validated index.
You can’t target what you don’t measure.
Abstr 0351 @ RheumNow #EULAR2026
#axSpA #PsA https://t.co/VAcoZfCXsR
At the "What Is New in Psoriatic Arthritis" session at EULAR 2026, Professor Dennis McGonagle (Leeds, UK) took the audience on a whirlwind yet compact tour of the field, touching on three themes: the pathophysiology of PsA, individualization of clinical management, and emerging research and future directions.
Nelly ZIADE 🍀 Nellziade
1 week 3 days ago
💉Do GLP-1 agonists improve DMARD persistence in PsA/axSpA?
TriNetX real-world study (n=3,068): YES!
Better b/tsDMARD persistence and lower stroke & mortality risk
#POS0194 #EULAR2026 @rheumnow
Nelly ZIADE 🍀 Nellziade
1 week 3 days ago
🔮 Can polygenic risk scores predict PsA timing in psoriasis?
Another GWAS study (n=703) says YES!
70-SNP model achieves AUC 0.843 for predicting PsA onset <10 vs >10 years
#POS0088 #EULAR2026 @RheumNow https://t.co/wI4Jy8Yu2A
Nelly ZIADE 🍀 Nellziade
1 week 3 days ago
🧪 Can genetics predict TNFi response in PsA?
OUTPASS GWAS (n=329): High BMI, comorbidities & novel XKR4 locus linked to non-response at 6 months
#POS0087 #EULAR2026 @rheumnow
